荃信生物(2509.HK)公布，拟按配售价每股20港元配售500万股新H股，集资1亿港元，净额为9900万港元，其中约60%用于偿还现有计息银行借款；约30%用于新管线研发；及约10%用作营运资金及其他企业用途。配售价较上周五收市价22.46港元折让约10.95%；配售股份占扩大后股本约2.2%。
荃信生物(2509.HK)公布，拟按配售价每股20港元配售500万股新H股，集资1亿港元，净额为9900万港元，其中约60%用于偿还现有计息银行借款；约30%用于新管线研发；及约10%用作营运资金及其他企业用途。配售价较上周五收市价22.46港元折让约10.95%；配售股份占扩大后股本约2.2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.